The treatment of venous thromboembolism in patients with cancer

Internal and Emergency Medicine

Volumn 5, Issue SUPPL. 1, 2010, Pages 27-30

  Prandoni, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer; Low molecular weight heparin; Oral anticoagulants; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE;

ARTICLE; CRITICAL ILLNESS; HUMAN; NEOPLASM; RECURRENT DISEASE; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CRITICAL ILLNESS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; POLYSACCHARIDES; RECURRENCE; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 77957128947     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0445-y     Document Type: Article

References (22)

1. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6: 401-410.
2. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78: 285-291.
3. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119: 60-68.
4. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR 189: 162-170.
5. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715-722.
6. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464.
7. Chew HK, Wun T, Harvey DJ, Zhou H, White RH (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25: 70-76.
8. Lee AY (2005) Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 128: 291-302.
9. Elting LS, Escalante CP, Cooksley C et al (2004) Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164: 1653-1661.
10. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl): 454-545.
11. Ageno W, Grimwood R, Limbiati S, Dentali F, Steidl L, Wells PS (2005) Home-treatment of deep vein thrombosis in patients with cancer. Haematologica 90: 220-224.
12. Siragusa S, Arcara C, Malato A et al (2005) Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol 16(suppl. 4): 136-139.
13. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800-809.
14. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 160: 181-188.
15. Investigators The Matisse (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695-1702.
16. Buller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 140: 867-873.
17. van Doormaal FF, Raskob GE, Davidson BL et al (2009) Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb Haemost 101: 762-769.
18. van Doormaal FF, Cohen AT, Davidson BL et al (2010) Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the van Gogh DVT trial. Thromb Haemost (in press).
19. Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342-2352.
20. Prandoni P, Lensing AWA, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484-3488.
21. Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153.
22. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 162: 1729-1735.